Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Psychosocial intervention vs control Functioning at study endpoint · promoting the mental health of people living in LMICs affected by humanitarian crises (children) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | 1 study · 183 participants | Very low |
Summary of findings table ‐ Psychosocial intervention vs control Functioning at · promoting the mental health of people living in LMICs affected by humanitarian crises (children) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | 1 study · 183 participants | Very low |
Summary of findings table ‐ Psychosocial intervention vs control Prosocial behaviour at study endpoint · promoting the mental health of people living in LMICs affected by humanitarian crises (children) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | 5 studies · 1633 participants | Low |
Summary of findings table ‐ Psychosocial intervention vs control Prosocial behaviour at · promoting the mental health of people living in LMICs affected by humanitarian crises (children) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | 2 studies · 483 participants | Very low |
Summary of findings table ‐ Psychosocial intervention vs control Mental well‐being at study endpoint · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | 3 studies · 674 participants | Low |
Summary of findings table ‐ Psychosocial intervention vs control Mental well‐being at · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | 1 study · 441 participants | Very low |
Summary of findings table ‐ Psychosocial intervention vs control Functioning at study endpoint ‐ not measured · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Emicizumab prophylaxis vs on‐demand therapy Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Annualized joint Bleeding Rate (AjBR) · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 57 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Change from baseline in total health score, Haem‐A‐QoLScale from: 0 (better) to 100 · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 48 participants | Low |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Proportion with zero bleeds · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 12.5 [1.83, 85.38] | 1 study · 57 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy All adverse events · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.6 [1.08, 2.37] | 1 study · 60 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Serious adverse events · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 0.65 [0.24, 1.78] | 1 study · 60 participants | Moderate |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Annualized Bleeding Rate (ABR), All bleeds · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 2 studies · 68 participants | Low |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 2 studies · 78 participants | Very low |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Annualized joint Bleeding Rate (AjBR) · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 2 studies · 78 participants | Low |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Proportion with zero bleeds · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 6.05 [1.59, 23] | 1 study · 52 participants | Low |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Change from baseline in SF‐36v2 ‐ mental component scoreScale from: 0 to 100 (better) · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Summary of findings table ‐ Emicizumab prophylaxis vs on‐demand therapy Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Adverse events ‐ All adverse events · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.14 [0.76, 1.7] | 2 studies · 78 participants | Low |
Summary of findings table ‐ Concizumab prophylaxis vs on‐demand therapy Adverse events ‐ Serious adverse events · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 0.45 [0.06, 3.38] | 2 studies · 78 participants | Low |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 54 participants | Moderate |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Annualized joint Bleeding Rate (AjBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 54 participants | Moderate |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 54 participants | Moderate |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Proportion of participants with zero bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 19 [1.21, 298.4] | 1 study · 54 participants | Low |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Change in Haem‐A‐QoL total score Scale from: 0 (better) to 100 · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 47 participants | Low |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy All adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 2.83 [1.47, 5.47] | 1 study · 54 participants | Moderate |
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Serious adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 0.5 [0.03, 7.54] | 1 study · 54 participants | Moderate |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicizumab prophylaxis vs on‐demand therapy Annualized joint Bleeding Rate (AjBR) · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy Annualized joint Bleeding Rate (AjBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy Proportion of participants with zero bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 15.31 [0.96, 242.76] | 1 study · 53 participants | Low |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy Change in total score, Haem‐A‐QoLScale from: 0 (better) to 100 · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 53 participants | Low |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy All adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.71 [1.06, 2.77] | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy Serious adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.54 [0.17, 13.79] | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 71 participants | Moderate |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Annualized joint Bleeding Rate (AjBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 71 participants | Moderate |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 71 participants | Moderate |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Proportion of participants with zero bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.25 [0.74, 2.1] | 1 study · 71 participants | Moderate |
Summary of findings table ‐ Emicizumab prophylaxis vs on‐demand therapy Proportion with zero bleeds · people with inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 11.31 [1.66, 77.3] | 1 study · 53 participants | Moderate |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Change in total score, Haem‐A‐QoL Scale from: 0 (better) to 100 · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks All adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.1 [0.04, 2.97] | 1 study · 71 participants | Moderate |
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Serious adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 0.32 [0.04, 2.97] | 1 study · 71 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 119 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Annualized joint Bleeding Rate (AjBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 119 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 119 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Proportion with zero bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 8.1 [2.04, 32.11] | 1 study · 119 participants | Moderate |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy Change in total scores, Haem‐A‐QoL Scale from: 0 (better) to 100 · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Low |
Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy All adverse events · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane | RR 1.74 [1.21, 2.5] | 1 study · 119 participants | Moderate |